Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG)
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
2013
|
| _version_ | 1797082356300906496 |
|---|---|
| author | Dutton, S Blazeby, J Petty, R Mansoor, W Thompson, J Harrison, M Abbas, H Dahle-Smith, A Chatterjee, A Falk, S Garcia-Alonso, A Fyfe, D Hubner, R Gamble, T Peachey, L Harvey, C Julier, P Jankowski, J Midgley, R Ferry, DR Grp, C |
| author_facet | Dutton, S Blazeby, J Petty, R Mansoor, W Thompson, J Harrison, M Abbas, H Dahle-Smith, A Chatterjee, A Falk, S Garcia-Alonso, A Fyfe, D Hubner, R Gamble, T Peachey, L Harvey, C Julier, P Jankowski, J Midgley, R Ferry, DR Grp, C |
| author_sort | Dutton, S |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-07T01:27:02Z |
| format | Journal article |
| id | oxford-uuid:92536180-a53c-4324-9594-d7cb15ec45d8 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T01:27:02Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:92536180-a53c-4324-9594-d7cb15ec45d82022-03-26T23:24:43ZPatient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:92536180-a53c-4324-9594-d7cb15ec45d8Symplectic Elements at Oxford2013Dutton, SBlazeby, JPetty, RMansoor, WThompson, JHarrison, MAbbas, HDahle-Smith, AChatterjee, AFalk, SGarcia-Alonso, AFyfe, DHubner, RGamble, TPeachey, LHarvey, CJulier, PJankowski, JMidgley, RFerry, DRGrp, C |
| spellingShingle | Dutton, S Blazeby, J Petty, R Mansoor, W Thompson, J Harrison, M Abbas, H Dahle-Smith, A Chatterjee, A Falk, S Garcia-Alonso, A Fyfe, D Hubner, R Gamble, T Peachey, L Harvey, C Julier, P Jankowski, J Midgley, R Ferry, DR Grp, C Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG) |
| title | Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG) |
| title_full | Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG) |
| title_fullStr | Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG) |
| title_full_unstemmed | Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG) |
| title_short | Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG) |
| title_sort | patient reported outcomes from a phase hi multicenter randomized double blind placebo controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy cancer oesophagus gefitinib cog |
| work_keys_str_mv | AT duttons patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT blazebyj patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT pettyr patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT mansoorw patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT thompsonj patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT harrisonm patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT abbash patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT dahlesmitha patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT chatterjeea patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT falks patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT garciaalonsoa patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT fyfed patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT hubnerr patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT gamblet patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT peacheyl patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT harveyc patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT julierp patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT jankowskij patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT midgleyr patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT ferrydr patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog AT grpc patientreportedoutcomesfromaphasehimulticenterrandomizeddoubleblindplacebocontrolledtrialofgefitinibversusplaceboinesophagealcancerprogressingalterchemotherapycanceroesophagusgefitinibcog |